Ro15-4513

Ro15-4513
Clinical data
Drug class	GABAA receptor inverse agonist
ATC code	None;
Identifiers
	IUPAC name Ethyl-8-azido-5,6-dihydro-5-methyl-6-oxo-4H-imidazo-1,4-benzodiazepine-3-carboxylate;
CAS Number	91917-65-6 ;
PubChem CID	5081;
IUPHAR/BPS	4296;
ChemSpider	4903 ;
UNII	S5XGL82O5Y;
ChEMBL	ChEMBL6597 ;
CompTox Dashboard (EPA)	DTXSID80238763 ;
Chemical and physical data
Formula	C15H14N6O3
Molar mass	326.316 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(OCC)C1=C2CN(C)C(C3=CC(N=[N+]=[N-])=CC=C3N2C=N1)=O;
	InChI InChI=1S/C15H14N6O3/c1-3-24-15(23)13-12-7-20(2)14(22)10-6-9(18-19-16)4-5-11(10)21(12)8-17-13/h4-6,8H,3,7H2,1-2H3 ; Key:CFSOJZTUTOQNIA-UHFFFAOYSA-N ;
	(what is this?) (verify)

Ro15-4513 is a weak partial inverse agonist of the benzodiazepine class of drugs, developed by Hoffmann–La Roche in the 1980s. It acts as an inverse agonist (which acts in a similar way as a competitive antagonist). The drug has been explored as possible antidote to the sedative and cognitively impairing effects of ethanol.

Ro15-4513 is structurally related to the benzodiazepine antidote flumazenil.